Chronic myeloid leukemia: a model disease of the past, present and future
VR Minciacchi, R Kumar, DS Krause - Cells, 2021 - mdpi.com
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …
The role of osteoblasts in the hematopoietic microenvironment
RS Taichman, SG Emerson - Stem cells, 1998 - academic.oup.com
Hematopoietic stem cell differentiation occurs in direct proximity to osteoblasts within the
bone marrow cavity. Despite this striking affiliation, surprisingly little is known about the …
bone marrow cavity. Despite this striking affiliation, surprisingly little is known about the …
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia
B Zhang, YW Ho, Q Huang, T Maeda, A Lin, S Lee… - Cancer cell, 2012 - cell.com
We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …
leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long …
[HTML][HTML] Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway
T Skorski, A Bellacosa, M Nieborowska‐Skorska… - The EMBO …, 1997 - embopress.org
The BCR/ABL oncogenic tyrosine kinase activates phosphatidylinositol 3‐kinase (PI‐3k) by
a mechanism that requires binding of BCR/ABL to p85, the regulatory subunit of PI‐3k, and …
a mechanism that requires binding of BCR/ABL to p85, the regulatory subunit of PI‐3k, and …
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr …
Bcr/Abl is a chimeric oncogene that can cause both acute and chronic human leukemias.
Bcr/Abl-encoded proteins exhibit elevated kinase activity compared to c-Abl, but the …
Bcr/Abl-encoded proteins exhibit elevated kinase activity compared to c-Abl, but the …
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial …
B GLEIßNER, N Gökbuget, CR Bartram… - Blood, The Journal …, 2002 - ashpublications.org
The BCR-ABL fusion, the molecular equivalent of the Philadelphia translocation, gains
importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this …
importance for treatment stratification in adult acute lymphoblastic leukemia (ALL). In this …
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5 …
Bcr-Abl–expressing leukemic cells are highly resistant to apoptosis induced by
chemotherapeutic drugs. Although a number of signaling molecules have been shown to be …
chemotherapeutic drugs. Although a number of signaling molecules have been shown to be …
An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles
JG Thomas, JM Olson, SJ Tapscott… - Genome Research, 2001 - genome.cshlp.org
We have developed a statistical regression modeling approach to discover genes that are
differentially expressed between two predefined sample groups in DNA microarray …
differentially expressed between two predefined sample groups in DNA microarray …
Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is …
M Nieborowska-Skorska, MA Wasik… - The Journal of …, 1999 - rupress.org
Signal transducer and activator of transcription (STAT) 5 is constitutively activated in
BCR/ABL-expressing cells, but the mechanisms and functional consequences of such …
BCR/ABL-expressing cells, but the mechanisms and functional consequences of such …
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
MS Holtz, ML Slovak, F Zhang… - Blood, The Journal …, 2002 - ashpublications.org
Imatinib mesylate (STI571) is a promising new treatment for chronic myelogenous leukemia
(CML). The effect of imatinib mesylate on primitive malignant progenitors in CML has not …
(CML). The effect of imatinib mesylate on primitive malignant progenitors in CML has not …